| SLB |
Report |
2Q26 adjusted EPS |
BEAT |
pred ~$0.54 vs. cons $0.52 |
MEDIUM |
| SLB |
Report |
2Q26 revenue |
IN-LINE |
pred ~$8.73B vs. cons $8.70B |
MEDIUM |
| SLB |
Report |
2Q26 adjusted EBITDA margin |
BEAT |
pred ~20.7% vs. cons 20.4% |
LOW |
| SLB |
Guide |
3Q26 adjusted EPS outlook |
LOWER |
guide ~$0.49 vs. cons $0.57 (3Q26) |
MEDIUM |
| SLB |
Guide |
3Q26 sequential revenue outlook |
LOWER |
guide ~-3% vs. cons +3% (3Q26) |
MEDIUM |
| SLB |
Guide |
2026 share-repurchase commitment |
UNCHANGED |
guide ~$2.4B vs. cons $2.4B (FY26) |
HIGH |
| SLB |
Return |
Day-1 residual (stock − beta × S&P 500) |
-4.5% |
— |
MEDIUM |
| SLB |
Return |
5-day cumulative residual |
-7.0% (FOLLOW-THROUGH) |
A modest 2Q EPS beat of ~$0.54 versus ~$0.52 is likely outweighed by implied 3Q EPS of ~$0.49 versus ~$0.57 consensus; the out-period cut should drive negative revisions after the print. |
MEDIUM |